Ioxilan is a low-osmolar, nonionic, and tri-iodinated diagnostic contrast agent used for excretory urography and contrast-enhanced computed tomographic (CECT) imaging of the head and body. When injected intravascularly, it opacifies vessels, enabling radiographic visualization of internal structures until significant hemodilution occurs.

The development of Ioxilan incorporates a dual methylene structure to act as a hydrophobic region, which is then concealed by a hydrophilic hydroxyl group. This modification reduces osmolality without compromising biological tolerance. As a low-osmolar, nonionic monomer, Ioxilan enhances the safety and tolerability of X-ray contrast agents.

Rapid intravenous injection of (water-soluble) X-ray contrast agents (Ioxilan), used in conjunction with dynamic computed tomography, enhances the visualization of liver lesions. These agents, primarily remaining in the extracellular fluid and excreted unchanged by the kidneys, distribute effectively post-injection. The degree of contrast enhancement in a specific region is influenced by the administration method, the delivery of the agent via blood flow, and the resultant iodine concentration in that area.